The agreement is the latest in a series of acquisitions and licensing deals aimed at bolstering AZ’s position in cell therapy, an area where it has lagged behind other companies like Novartis, Bristol-Myers Squibb, and Gilead Sciences, and also continues a string of agreements it has signed with Chinese companies.
If consummated, the deal will add a BCMA and CD19-targeted CAR-T therapy for blood cancers including relapsed and refractory multiple myeloma, for which it is in a phase 1b/2 trial in the US.
